# Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Study · id `cardio:ct-nct05769868` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05769868](<https://clinicaltrials.gov/study/NCT05769868>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05769868

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT05769868. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-04-18 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT05769868, source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)
- Started: 2023-04-18 (actual) (ClinicalTrials.gov record NCT05769868, source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT05769868, source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT05769868, source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05769868, source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05769868-2024-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
- Acronym: CIBERbBECHO
- Condition: Cirrhosis
- Condition: Diabetes Mellitus
- Condition: Oncologic Disorders
- Intervention (Drug): Esmolol Injection \[Brevibloc\]
- Lead sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Lead sponsor class: OTHER\_GOV
- Collaborator: Instituto de Salud Carlos III
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Instituto de Salud Carlos III (`cardio:org-instituto-de-salud-carlos-iii`)

## Provenance

Content hash: eecba5505989d69c988cdda01e6129553e08f27ba4e46384dcd2b0638e469c9f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
